Angiotensin II and its role in tubular epithelial to mesenchymal transition associated with chronic kidney disease.
Activation of the intra-renal renin-angiotensin system (RAS) and the subsequent generation of angiotensin II (Ang II) are important mediators of haemodynamic changes in both health and disease. However, the effects of locally produced Ang II are not limited to haemodynamic actions. Ang II is also an important stimulus for tubular hypertrophy with the induction of growth factors, including transforming growth factor (TGF)-β(1) and connective tissue growth factor. In this article, we explore the direct pro-fibrotic effects of Ang II and its role in inducing tubular epithelial to mesenchymal transition (EMT, also known as type 2 EMT), a known mediator of renal fibrogenesis. There is accumulating evidence that Ang II is able to induce EMT by both TGF-dependent and TGF-independent actions, both in vitro and in vivo. Moreover, blockade of the RAS has synergistic renoprotective effects across a number of causally different forms of renal disease. There is hope that targeted combinations to offset angiotensin-converting enzyme escape in the setting of RAS blockade will eventually achieve the long-term efficacy that has been expected for so long.
Danielle Alberti Memorial Centre for Diabetes Complications, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia. wendy.burns@bakeridi.edu.au
W C
WC
Burns
M C
MC
Thomas
D000804:Angiotensin II / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D058750:Epithelial-Mesenchymal Transition / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007674:Kidney Diseases / Q000235:genetics / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000235:genetics / Q000502:physiology*
D000804:Angiotensin II